BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Jhaveri R, Yee LM, Antala S, Murphy M, Grobman WA, Shah SK. Responsible Inclusion of Pregnant Individuals in Eradicating HCV. Hepatology 2021. [PMID: 33743550 DOI: 10.1002/hep.31825] [Reference Citation Analysis]
2 Aboras SI, Abdine HH, Ragab MAA, Korany MA. A Review on Analytical Strategies for the Assessment of Recently Approved Direct Acting Antiviral Drugs. Crit Rev Anal Chem 2021;:1-23. [PMID: 34138669 DOI: 10.1080/10408347.2021.1923456] [Reference Citation Analysis]
3 Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol Immunol 2021;65:352-72. [PMID: 33990999 DOI: 10.1111/1348-0421.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Trooskin S, Jhaveri R. Conversations With the Editors: Hepatitis C Virus-Where are We Now and Where Do We Go From Here? Clin Ther 2020;42:1425-32. [PMID: 32778344 DOI: 10.1016/j.clinthera.2020.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 El Kassas M, Salah E, Gad A, Hosny A. Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals. Curr Med Res Opin 2021;37:967-72. [PMID: 33688780 DOI: 10.1080/03007995.2021.1901677] [Reference Citation Analysis]
6 Elsadek HM, Abdelbaser ES, Emara MH, Soliman HH, Farag AA. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. Eur J Gastroenterol Hepatol 2020;32:1046-53. [PMID: 33216478 DOI: 10.1097/MEG.0000000000001695] [Reference Citation Analysis]
7 Saif-Al-Islam M, Abdelaal UM, Younis MA, Alghany Algahlan HA, Khalaf S. Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. Gastroenterol Res Pract 2021;2021:8811203. [PMID: 34122539 DOI: 10.1155/2021/8811203] [Reference Citation Analysis]
8 Wang AE, Hsieh E, Turner BJ, Terrault N. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. J Gen Intern Med 2022. [PMID: 35484367 DOI: 10.1007/s11606-022-07628-9] [Reference Citation Analysis]
9 Sherief LM, Ragab SM, Helwa MA, Kamal NM, Afify MR, Mohammed RTS, Mokhtar GAE, Sherbiny HS. CMV, B and C hepatitis among multi-transfused hereditary hemolytic Anemia children: an updated Egyptian experience. Ital J Pediatr 2021;47:117. [PMID: 34039385 DOI: 10.1186/s13052-021-01072-x] [Reference Citation Analysis]
10 Toson EA, Shiha GE, El-Sharkawy AM, El-Mezayen HA. Diagnostic performance of extrinsic apoptosis pathway in hepatitis C virus patients: apoptosis fibrosis crosstalk. Eur J Gastroenterol Hepatol 2020;32:990-7. [PMID: 31743229 DOI: 10.1097/MEG.0000000000001603] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 El-sakka AI. Middle East Cultural Challenges and the Treatment of Sexual Problems in Men. In: Rowland DL, Jannini EA, editors. Cultural Differences and the Practice of Sexual Medicine. Cham: Springer International Publishing; 2020. pp. 135-48. [DOI: 10.1007/978-3-030-36222-5_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 El Kassas M, Abdelkader H, Medhat MA. COVID-19 in Egypt: Through crisis to adaptation; a gastroenterologist's perspective. Arab J Gastroenterol. 2020;21:207-210. [PMID: 32798187 DOI: 10.1016/j.ajg.2020.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Corma-gómez A, Pineda JA. Hepatitis C virus infection in Spain: Challenges in the track to elimination. Enfermedades Infecciosas y Microbiología Clínica 2019;37:219-21. [DOI: 10.1016/j.eimc.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sharafi H, Alavian SM. The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017. Clin Liver Dis (Hoboken) 2019;14:219-23. [PMID: 32015873 DOI: 10.1002/cld.890] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Teama NM, Abdel-mohsen WA, Ahmed OA, El Sayed SM, Elghandour AM. Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00079-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hagag RS, Fakhry MM, Ahmed OA, Abdalgeleel SA, Radwan MA, Naguib GG. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00126-8] [Reference Citation Analysis]
17 Behairy BE, El-Araby HA, El-Guindi MA, Basiouny HM, Fouad OA, Ayoub BA, Marei AM, Sira MM. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. J Pediatr 2020;219:106-10. [PMID: 32008767 DOI: 10.1016/j.jpeds.2019.12.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Beaumont E, Joël Clément B, Guérin V, Chopin L, Roch E, Gomez-Escobar E, Roingeard P. Mixing particles from various HCV genotypes increases the HBV-HCV vaccine ability to elicit broadly cross-neutralizing antibodies. Liver Int 2020;40:1865-71. [PMID: 32458507 DOI: 10.1111/liv.14541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Abd El-Wahab EW, Metwally M, Lotfy N. Effectiveness of hepatitis B vaccination in chronic HCV patients after successful generic direct acting antiviral therapy: significance of isolated hepatitis B core antibodies. Trop Med Int Health 2021;26:882-94. [PMID: 33860608 DOI: 10.1111/tmi.13588] [Reference Citation Analysis]
20 Khalsa JH, Mathur P. Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. Viruses 2021;13:1363. [PMID: 34372569 DOI: 10.3390/v13071363] [Reference Citation Analysis]
21 Negm EM. Does mass management of chronic hepatitis C protect the Egyptian population against fulminant coronavirus disease-2019? “Postulating a hypothesis”. Egypt J Bronchol 2022;16. [DOI: 10.1186/s43168-022-00120-2] [Reference Citation Analysis]
22 Nomair AM, Issa NM, Madkour MA, Shamseya MM. The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma. Clin Exp Hepatol 2020;6:20-7. [PMID: 32166120 DOI: 10.5114/ceh.2020.93052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, Leung J, Grebely J, Larney S, Martin NK, Degenhardt L, Hickman M, May MT, Vickerman P. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. J Viral Hepat 2019;26:1388-403. [PMID: 31392812 DOI: 10.1111/jvh.13187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 El-Bendary M, Abd-Elsalam S, Elbaz T, El-Akel W, Cordie A, Elhadidy T, Elalfy H, Farid K, Elegezy M, El-Badrawy A, Neamatallah M, Abd Elghafar M, Salama M, AbdAllah M, Essam M, El-Shazly M, Esmat G. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34225541 DOI: 10.1080/14787210.2021.1950532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Massoud O. Hepatitis C: looking into the future. Expert Rev Gastroenterol Hepatol 2020;14:367-74. [PMID: 32216467 DOI: 10.1080/17474124.2020.1746641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tabll A, El Shenawy R, Elsharkawy H, Mohamed FZ. Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients. Hum Antibodies 2019;27:265-73. [PMID: 31127759 DOI: 10.3233/HAB-190381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Umutesi G, Shumbusho F, Kateera F, Serumondo J, Kabahizi J, Musabeyezu E, Ngwije A, Gupta N, Nsanzimana S. Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa. J Hepatol. 2019;70:1043-1045. [PMID: 30948269 DOI: 10.1016/j.jhep.2019.03.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
28 Saleh EM, Gouda AE, Medhat AM, Ahmed HO, Shemis MA. Expression of HCV genotype-4 core antigen in prokaryotic E. coli system for diagnosis of HCV infection in Egypt. Protein Expr Purif 2021;188:105965. [PMID: 34461217 DOI: 10.1016/j.pep.2021.105965] [Reference Citation Analysis]
29 El Sayed ML, Gouda TES, Khalil ELSAM, Al Arman MMES, Mohamed IE. Clinical profile and outcome among patients with acute-on-chronic liver failure admitted in the intensive care unit. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00061-0] [Reference Citation Analysis]
30 Jhaveri R. Screening for Hepatitis C Virus: How Universal Is Universal? Clin Ther 2020;42:1434-41. [PMID: 32712026 DOI: 10.1016/j.clinthera.2020.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Alhaddad O, Elsabaawy M, Elshaaraawy O, Elhalawany M, Houseni MM, Abdelsameea E. Portal vein thrombosis in hepatitis C virus-related cirrhotic patients: Prevalence and clinical characteristics in an Egyptian cohort. Trop Doct 2021;51:314-8. [PMID: 33663297 DOI: 10.1177/0049475521998509] [Reference Citation Analysis]
32 Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction 2020;115:1244-62. [PMID: 32009283 DOI: 10.1111/add.14944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Sabry N, ElHadidi S, Kamel A, Abbassi M, Farid S. Awareness of the Egyptian public about COVID-19: what we do and do not know. Inform Health Soc Care 2021;46:244-55. [PMID: 33622157 DOI: 10.1080/17538157.2021.1883029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021;45:101596. [PMID: 33610022 DOI: 10.1016/j.clinre.2020.101596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
36 Esmat G, Elbaz T, Elsharkawy A, Abdullah M, El Kassas M. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Rev Anti Infect Ther 2020;18:637-42. [PMID: 32302245 DOI: 10.1080/14787210.2020.1758065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Moustafa H, Madkour M, Hamed F, Abouelnazar S, Abo Elwafa R, Moaaz M. Modulation of Memory B Cell Phenotypes and Toll-Like Receptor-7 in Chronic Hepatitis C Virus Infection During Direct-Acting Antiviral Interferon-Free Therapy: Correlation with Interleukin-7. Viral Immunol 2021;34:227-40. [PMID: 33180667 DOI: 10.1089/vim.2020.0110] [Reference Citation Analysis]
38 Shousha HI, Said M, ElAkel W, ElShafei A, Esmat G, Waked E, Elsayed MH, Doss W, Elrazky M, Mehrez M, Hassany M, Zeyada D, Anis M, Alserafy M. Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles. J Infect Public Health 2020;13:1322-9. [PMID: 32473817 DOI: 10.1016/j.jiph.2020.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Yasser MB, Abdellatif M, Emad E, Jafer A, Ahmed S, Nageb L, Abdelshafy H, Al-Anany AM, Al-Arab MAE, Gibriel AA. Circulatory miR-221 & miR-542 expression profiles as potential molecular biomarkers in Hepatitis C Virus mediated liver cirrhosis and hepatocellular carcinoma. Virus Res 2021;296:198341. [PMID: 33607184 DOI: 10.1016/j.virusres.2021.198341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Dhiman RK, Grover GS, Premkumar M. Hepatitis C elimination: a Public Health Perspective. Curr Treat Options Gastro 2019;17:367-77. [DOI: 10.1007/s11938-019-00240-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
41 Meshrif WS, El-kholy SE, El-husseiny IM, Dawood R, El-azm AA, Salem ML. Reduced fitness of the mosquito Culex pipiens (Diptera: Culicidae) after feeding on a blood meal with hepatitis C virus. Journal of Invertebrate Pathology 2022. [DOI: 10.1016/j.jip.2022.107719] [Reference Citation Analysis]
42 Schwander B, Feldstein J, Sulo S, Gonzalez L, ElShishiney G, Hassany M. Pursuing Elimination of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide Program. Infect Dis Ther 2022. [PMID: 35451742 DOI: 10.1007/s40121-022-00631-x] [Reference Citation Analysis]
43 Metwally AM, Elmosalami DM, Elhariri H, El Etreby LA, Aboulghate A, El-Sonbaty MM, Mohsen A, Saleh RM, Abdel-Latif GA, Samy S, El Deeb SE, Fathy AM, Salah MM, Abdel Mawla MA, Imam HM, Ibrahim NA, Shaaban FA, Elamir RY, Abdelrahman M, El-Sayed MH. Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study. PLoS One 2021;16:e0242257. [PMID: 33621232 DOI: 10.1371/journal.pone.0242257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-22. [PMID: 33069326 DOI: 10.1016/S0140-6736(20)30925-9] [Cited by in Crossref: 1408] [Cited by in F6Publishing: 833] [Article Influence: 704.0] [Reference Citation Analysis]
45 El-Maraghy SA, Adel O, Zayed N, Yosry A, El-Nahaas SM, Gibriel AA. Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis. J Adv Res 2020;22:57-66. [PMID: 31956442 DOI: 10.1016/j.jare.2019.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
46 El-Saaidi C, Dadras O, Musumari PM, Ono-Kihara M, Kihara M. Infection Control Knowledge, Attitudes, and Practices among Students of Public Dental Schools in Egypt. Int J Environ Res Public Health 2021;18:6248. [PMID: 34207772 DOI: 10.3390/ijerph18126248] [Reference Citation Analysis]
47 Mera J, Williams MB, Essex W, McGrew KM, Boeckman L, Gahn D, Miller A, Durham D, Fox J, David C, Ritter T, Jones S, Bouse S, Galvani A, Ward JW, Drevets DA, Carabin H. Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program in the First 22 Months of Implementation. JAMA Netw Open 2020;3:e2030427. [PMID: 33337496 DOI: 10.1001/jamanetworkopen.2020.30427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
49 Gull N, Arshad F, Naikoo GA, Hassan IU, Pedram MZ, Ahmad A, Aljabali AAA, Mishra V, Satija S, Charbe N, Negi P, Goyal R, Serrano-Aroca Á, Al Zoubi MS, El-Tanani M, Tambuwala MM. Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma. J Gastrointest Cancer 2022. [PMID: 35285010 DOI: 10.1007/s12029-022-00809-z] [Reference Citation Analysis]
50 Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog 2021;162:105311. [PMID: 34843922 DOI: 10.1016/j.micpath.2021.105311] [Reference Citation Analysis]
51 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
52 Elsayed A, M Abdelraheem E, Hassan H, Abbas A, Hassnine A. Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect? BMJ Open Gastroenterol 2020;7:e000533. [PMID: 33310750 DOI: 10.1136/bmjgast-2020-000533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Reference Citation Analysis]
54 Hassan GS, Georgey HH, Mohammed EZ, Omar FA. Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors. Eur J Med Chem 2019;184:111747. [PMID: 31604164 DOI: 10.1016/j.ejmech.2019.111747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
55 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
56 Abdelaziz H, Omar H, Khalil M, Cordie A, Mohamed R, AbdAllah M, Abdel Maksoud MH, El Garhy N, Ali L, El Serafy M, Esmat G, Doss W. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34751609 DOI: 10.1080/14787210.2022.2004117] [Reference Citation Analysis]
57 Medhat MA, El-kassas M, Karam-allah H, Al Shafie A, Abd-elsalam S, Moustafa E, Hassany SM, Salama M, Abd Elghafar MS, Sayed H, Badr M, Kamal DT, Shamseldeen A, Ossimi A, Moaz I, El-deen Esmael H, Ezz Eldin AM, Ezzat S, Abdelghaffar H, Abdelghaffar K. Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals. Arab Journal of Gastroenterology 2022. [DOI: 10.1016/j.ajg.2022.04.005] [Reference Citation Analysis]
58 Salum GM, Dawood RM, Abd El-Meguid M, Ibrahim NE, Abdel Aziz AO, El Awady MK. Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes Dis 2020;7:392-400. [PMID: 32884993 DOI: 10.1016/j.gendis.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
59 El Kassas M, Hegazy OM, Salah EM. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations. World J Hepatol 2020; 12(10): 841-849 [PMID: 33200021 DOI: 10.4254/wjh.v12.i10.841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]